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Abstract
Background: Pneumonia is a major risk factor of death after acute stroke. In a mouse model, preventive antibacterial
therapy with moxifloxacin not only prevents the development of post-stroke infections, it also reduces mortality, and
improves neurological outcome significantly. In this study we investigate whether this approach is effective in stroke
patients.
Methods: Preventive ANtibacterial THERapy in acute Ischemic Stroke (PANTHERIS) is a randomized, double-blind, placebo-
controlled trial in 80 patients with severe, non-lacunar, ischemic stroke (NIHSS.11) in the middle cerebral artery (MCA)
territory. Patients received either intravenous moxifloxacin (400 mg daily) or placebo for 5 days starting within 36 hours
after stroke onset. Primary endpoint was infection within 11 days. Secondary endpoints included neurological outcome,
survival, development of stroke-induced immunodepression, and induction of bacterial resistance.
Findings: On intention-to treat analysis (79 patients), the infection rate at day 11 in the moxifloxacin treated group was
15.4% compared to 32.5% in the placebo treated group (p=0.114). On per protocol analysis (n=66), moxifloxacin
significantly reduced infection rate from 41.9% to 17.1% (p=0.032). Stroke associated infections were associated with a
lower survival rate. In this study, neurological outcome and survival were not significantly influenced by treatment with
moxifloxacin. Frequency of fluoroquinolone resistance in both treatment groups did not differ. On logistic regression
analysis, treatment arm as well as the interaction between treatment arm and monocytic HLA-DR expression (a marker for
immunodepression) at day 1 after stroke onset was independently and highly predictive for post-stroke infections.
Interpretation: PANTHERIS suggests that preventive administration of moxifloxacin is superior in reducing infections after
severe non-lacunar ischemic stroke compared to placebo. In addition, the results emphasize the pivotal role of
immunodepression in developing post-stroke infections.
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Introduction
The prognosis of stroke mainly depends on the incidence of
complications [1,2]. Stroke-associated pneumonia, occurring in 7
to 22% [3], is one of the main severe complications [4,5] and
thought to be the most common cause of poor outcome and death
in stroke patients [6–8]. The risk for pneumonia is highest in the
acute state of stroke [9] and in patients with non-lacunar strokes in
the MCA territory [7]. Several risk factors contribute to the
increased susceptibility of stroke patients for infections: aspiration
due to drowsiness, impaired bulbar reflexes, dysphagia, and
hypostasis in bed-ridden patient’s, as well as the need for invasive
PLoS ONE | www.plosone.org 1 May 2008 | Volume 3 | Issue 5 | e2158medical procedures [10]. Recently, we demonstrated in a mouse
stroke model that infections and mortality can effectively be
reduced, and neurological outcome improved by preventive
antibacterial therapy with the fluoroquinolone antibiotic moxi-
floxacin [11]. Based on these findings we designed the
PANTHERIS trial to investigate whether preventive antibacterial
short-term therapy (PAT) reduces the incidence of infections
compared to the current standard therapy. In an explorative
fashion we tested whether PAT also reduces mortality and
improves neurological outcome. To evaluate the safety of the
proposed preventive regimen of treatment we tested whether PAT
promotes resistance among facultative pathogenic bacteria.
Finally, we seek for underlying immunological mechanisms of
increased infectious susceptibility after stroke.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
This investigator initiated study was designed as a randomized,
double-blind, placebo-controlled trial in two academic centers
(Charite ´ Campus Mitte, Charite ´ Campus Benjamin Franklin) and
one community hospital (Unfallkrankenhaus Berlin), and was
conducted between May 2003 and July 2006. The protocol was
approved by the local ethics committee. Informed consent was
obtained from the patient or their legal guardian. PANTHERIS
was registered with ISRCTN74386719 at Current Controlled
Trials (http://www.controlled-trials.com/ISRCTN74386719).
Data safety was independently monitored and audited by local
monitoring authorities (Koordinationszentrum fu ¨r klinische Stu-
dien, KKS Charite ´). Study entry criteria were the occurrence of an
acute ischemic stroke (between 9 and 36 h after onset) in the MCA
territory with a score of at least 12 on the National Institute of
Health Stroke Scale (NIHSS), and patient age of at least 18 years.
Exclusion criteria were: hemorrhagic stroke, clinical signs of
infection on admission, contraindications against moxifloxacin,
preceding or ongoing antibiotic therapy within the last 24 h,
participation in another interventional trial, or immunosuppres-
sant treatment within the last 30 days. In order to avoid inclusion
of lacunar strokes, only patients with signs of cortical involvement
(e.g. aphasia, neglect) or with disturbances of consciousness in
addition to hemiparesis were included if initial CT scan was
negative for signs of ischemic stroke. We used a computer
generated allocation schedule. Because of the greater number of
strata, an adaptive randomization was adopted, including sex,
affected MCA territory, age (#64 vs. .64), and centre as
stratifying factors [12]. Trial pharmacists in each site labelled
the trial drugs with sequential study numbers according to
randomisation lists prepared by the trial statistician and dispensed
the drugs. Study investigators and enrolling stuff were masked to
the assignment.
Patients were randomly assigned to receive a daily iv infusion
over 60 minutes either verum [n=40, moxifloxacin 400 mg/
250 mL solution for infusion (AvaloxH, Bayer Vital GmbH)] or
placebo [n=40, riboflavin as a colorant, 20 mg/250 mL NaCl
0.9%] for five days starting within 36h after stroke onset. Verum
and placebo medication were visually indistinguishable. In case of
an intercurrent infection warranting treatment, in both groups the
study medication was continued and supplemented by a treatment
following predefined schemes: Treatment of 1) pneumonia:
361 g/d iv ceftazidime and 165 mg/kg bw/d iv tobramycin; 2)
endocarditis/bacteriemia: 261g/d iv vancomycin 3) urinary tract
infections: 26400 mg iv ciprofloxacin. However, when infections
were refractory to therapy, study medication could be discontin-
ued, and treatment could be adapted following medical reasoning.
After admission all patients underwent cranial CT scanning to
exclude intracranial hemorrhage. Patients were treated on stroke
units according to recommendations of the European stroke
initiative [13]. C-reactive protein was measured daily. Neurolog-
ical diagnostic work up aimed at identification of stroke cause,
which was classified following TOAST criteria [14]. Comorbidity
factors were recorded. Neurological deficit was measured at
admission and on days 2, 6, and 11 using NIHSS [15].
Primary endpoint was the infection rate within 11 days after
stroke onset. The day when infection occurred refers to the day
after stroke onset and not study treatment initiation. Infections
were diagnosed according to modified criteria of the U.S. Centers
for Disease Control and Prevention (CDC): Pneumonia was
diagnosed when at least one of the first and one of the latter
criteria were fulfilled: A) abnormal respiratory examination,
pulmonary infiltrates in chest x-rays; B) productive cough with
purulent sputum, microbiological cultures from lower respiratory
tract or blood cultures, leukocytosis, and elevation of C-reactive
protein (CRP). Diagnosis of urinary tract infection (UTI) was
based on two of the following criteria: fever (.38?0uC), urine
sample positive for nitrite, leucocyturia, and significant bacteriuria.
Secondary endpoint measures were survival and functional
outcome (Barthel Index [16]; BI) at day 180 after stroke. BI was
dichotomized into good (BI$60) and bad outcomes (BI,60).
Quantitative or semiquantitative cultures from lower respiratory
tract (sputum, tracheobronchial or bronchoalveolar lavage), urine,
and blood cultures (BacT/Alert FA aerobic and anaerobic bottles,
Biomerieux, INC. Durham, NC 27704, USA) were performed in
each case of infection. Urine samples were obtained from
previously inserted urinary catheters. Significant bacteriuria was
considered when .10
4 cfu/mL of a uropathogen were isolated.
Quantitative cultures of bronchoalveolar lavage or tracheobron-
chial samples have used a diagnostic threshold of .10
4 cfu/mL
and of .10
5 cfu/mL, respectively. Species identification and
antimicrobial susceptibility testing (microbroth dilution test)
followed standard operating procedures according to Clinical
and Laboratory Standards Institute (CLSI). For isolation,
identification and susceptibility testing of E. coli isolates before
(day 1) and after treatment (day 9) with moxifloxacin or placebo,
stool samples of each patient were cultured on TBX-Chromogen-
Agar (Tryptone Bile-X-Glucoronic Agar-SIFIN GmbH, Berlin,
Germany). After overnight incubation at 37uC, ten individual
putative E. coli colonies were isolated. Following additional
biochemical identification with VITEK2/GN-cards (Biomerieux,
INC. Durham, NC 27704, USA) minimal inhibitory concentra-
tions (MICs) of all E. coli isolates were determined by microdilution
testing according to CLSI standards for ciprofloxacin (MIC
#1 mg/L susceptible, MIC $4 mg/L resistant) and according to
the European Committee on Antimicrobial Susceptibility Testing
for moxifloxacin (MIC #0.5 mg/L susceptible, $2 mg/L resis-
tant). E. coli isolates were further investigated for the presence of
known mutations in the quinolone resistance determining region
(QRDR) of the DNA gyrase subunit A gene gyrA. The gyrA (Ser-
83) mutation was detected in isolated DNA by the mismatch
amplification mutation assay (MAMA) as described earlier [17].
Expression of human leukocyte antigen-DR (HLA-DR) on
monocytes was determined by flow cytometry using a highly
standardized quantitative assay as described earlier [18]. Briefly,
on days 1, 3, 8, 90, and 180 50 ml of EDTA-blood was stained
with 20 ml of monoclonal phycoerythrin-conjugated anti-human
leukocyte antigen-DR (HLA-DR) antibodies and peridin
chlorophyll (PerCP-Cy5.5)-conjugated anti-CD14-antibodies
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TM, Becton Dickinson) for 30 min in the dark at room
temperature. For lysis of erythrocytes, samples were incubated
with 500 ml FACS Lysing solution (Becton Dickinson) for 15 min
in the dark at room temperature. Subsequently, cells were washed
with 1 ml of FACS buffer and analyzed on a FACS Calibur
flowcytometer using CellQuest software after QuantiBrite calibra-
tion for 1:1 quantification. Final analysis was performed using
Quanticalc software (all from Becton Dickinson) to obtain the
molecules HLA-DR per cell from the measured geometric means.
The inter-assay CV was ,5% and the inter-lab CV of this assay
was ,20% [19].
Statistical analysis
Based on a retrospective analysis of infection rates in patients
with acute ischemic stroke in the MCA territory treated in the
participating centers (data not shown), an infection rate of 40% in
the placebo group, and 10% in the group treated with
moxifloxacin was assumed. A priori power analysis revealed that
a sample size of n=32 per group was needed (two-sided a=5%,
power 80%). With an estimated drop out rate of 20%, 40 patients
per group were needed for enrolment. After enrolment of the last
patient a blinded review meeting assessed study patients with
respect to protocol violations, which were labelled as ‘‘invalid’’ for
per protocol analysis. The efficacy of preventive antibacterial
therapy in reducing the incidence of post-stroke infections was
investigated using the per protocol population as the main analysis set
instead of the intention to treat approach in this phase IIb trial.
Continuous variables were described using arithmetic mean,
standard deviation, and 95% confidence interval (CI) for normally
distributed data, or median and range for non-normally
distributed data, respectively. Normal distribution was checked
by Q-Q-Plots and tested using the modified Kolmogorov-Smirnov
test [20]. Absolute and relative frequencies were used for
dichotomous variables. The infection rates (and other proportions)
of placebo and verum group were compared using Fisher’s exact
test and the Cochran-Mantel-Haenszel-test, stratified for study
centers. For analysis of CRP levels and daily maximum body
temperature the multivariate repeated measures analysis of
variance was done as described previously [21]. Differences in
CRP values between treatment groups were analyzed based on a
mixed model of logarithmically transformed data. The parameters
day and treatment are assumed fixed, the factor patient is assumed
random. Measurements between patients are assumed indepen-
dent distributed. Within patients a common, otherwise arbitrary
covariance matrix is assumed. The following models were used.
For the ‘‘no interaction model‘‘: log(CRPij,p)=m+ai+tj+p(tj)+eij.,
for the ‘‘interaction model’’: log(CRPij,p)=m+ai+tj+cij+p(tj)+eij,
where m is the grand mean, ai the day (i=1, 2, 3, 4, 5, 6, 7, 9, 11),
tj the treatment (j=1 for verum, 2 for placebo), p(tj) the patient
nested within treatment, cij the interaction treatment by day, and
eij the error term. In order to analyse the impact of risk factors for
stroke-associated infection multivariately, we used a multivariate
logistic regression analysis, including the calculation of odds ratios
and the corresponding 95% confidence intervals. Feature selection
(in reduction steps) was applied to show the most important
influencing (independent) factors. The clinical characteristics of
both treatment groups and of patients without and with infection
were compared in univariate analyses by Student’s t test for
continuous variables with a normal distribution. For non-normal
data and categorical variables the Mann-Whitney U test and the
Chi-Square test for few categories were used, respectively. Survival
in treatment and infection groups was calculated according to
Kaplan-Meier and compared univariately with Log-Rank-statis-
tics. Multiple tests for differences between the groups in question
have been regarded as exploratory ones and were not adjusted for
multiplicity. A two-tailed p,0.05 was considered statistically
significant. The statistical analysis used the Software Package for
Social Sciences, SPSS for Windows, 13.0, SPSS, Inc., Chicago, IL
and SAS, Version 9.1, by SAS Institute, Inc., Cary, NC, USA.
Results
Study population
Eighty patients with acute ischemic stroke were randomized.
For one patient informed consent was withdrawn before receiving
study medication. Therefore, 79 patients were included into
intention-to-treat (ITT) analysis (verum n=39; placebo n=40).
Baseline characteristics were similarly matched in both treatment
groups (Table 1), except for coronary heart disease which occurred
more frequent in the verum group (p=0.05). 66 patients (verum
n=35; placebo n=31) were analysed per protocol (PP). Eight
patients, who neither reached the primary endpoint nor completed
the study protocol until day 11 had to be excluded from the PP
analysis: Four patients (1 verum, 3 placebo) died within 3 days. In
three patients, study medication was discontinued due to medical
reasons (withdrawal of life supporting therapy, hemicraniectomy,
blinding opened due to a suspected CNS infection as the cause of
the neurological deficits instead of ischemic stroke). In one patient
informed consent was withdrawn. Five additional patients (3
verum, 2 placebo) were retrospectively excluded due to protocol
violations (e.g. allocated in infection group while failing predefined
infection criteria) and considered ‘‘invalid’’ in the blinded
reviewing process (Figure 1).
Primary endpoint: Prevention of post-stroke infections
In the ITT population (n=79; Table 2A), 19 patients (24.1%)
developed infections within 11 days after stroke onset. Six patients
(15.4%) treated with moxifloxacin developed an infection as
compared with 13 patients (32.5%) in the placebo group (17.1%
reduction, Fisher exact: p=0.114; Mantel-Haenszel-test stratified
for centres: p=0.068). In PP population (n=66) infection rate
with n=6 in the moxifloxacin group (17.1%) was significantly
lower (Fisher exact: p=0.032; Mantel-Haenszel: p=0.033)
Figure 1. PANTHERIS trial profile.
doi:10.1371/journal.pone.0002158.g001
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The reduction of 24.8% (95% CI 2.8%–44.3%) approximates to a
number needed to treat (NNT) of 4 (95% CI 2.3–35.3). Treatment
with moxifloxacin led to a relative risk reduction of 46.4% in ITT
and 59.1% in PP analyses, respectively. A difference in infection
rate between both groups emerged between day 2 and 4 and was
maintained until day 11 after stroke onset (data not shown). In
either population 11 patients suffered from pneumonia (3 verum, 8
placebo) and 8 patients had a urinary tract infection (3 verum, 5
placebo). On average, pneumonia was diagnosed 4.7 days (62.5)
after stroke, and urinary tract infection after 5.2 days (62.9). In
the ITT population the incidence of pneumonia was 8/40 (20.0%)
of the placebo group compared with 3/39 (7.7%) of the verum
group (12.3% reduction, p=0.193). In the PP population 8/31
(25.8%) of placebo treated patients suffered from pneumonia,
compared to 3/35 (8.6%) of the verum group (reduction 17.2%;
p=0.097). The incidence for urinary tract infections was similar
for both treatment groups [ITT: 3/39 (7.7%) verum vs. 5/40
(12.5%) placebo; p=0.712; PP: 3/35 (8.6%) verum vs. 5/31
(16.1%) placebo; p=0.459).
Table 1. Baseline characteristics
Placebo (n=40) Verum (n=39) p
n% n %
Centre 1 25 62.5 22 56.4 0.65
Centre 2 11 27.5 10 25.6 1.00
Centre 3 4 10.0 7 18.0 0.35
Male/female 14/26 35.0/65.0 15/24 38.5/61.5 0.82
Right/left MCA 18/22 45.0/55.0 20/19 51.3/48.7 0.66
Mean age (years) (95%CI) 72?7 68.6–76.9 72.4 68.8–76.1 0.80
NIHSS ad admission (Median,min-max) 15 12–25 17 12–21 0.66
Qualifying event
Cardioembolism 19 47.5 16 41.0 0.65
Atherothrombotic 12 30.0 14 35.9 0.64
Small-vessel 2 5.0 1 2.6 1.00
Other 2 5.0 3 7.7 0.66
Unknown 5 12.5 5 12.8 1.00
Risk factors
Hypertension 24 60.0 27 69.2 0.48
Diabetes mellitus 13 32.5 12 30.8 1.00
Current smoking 61 5 ?0 3 7.7 0.48
Hypercholesterolaemia 6 15.0 5 12.8 1.00
Atrial fibrillation 16 40.0 11 28.2 0.34
Malignancy 4 10.0 3 7.7 1.00
Coronary heart disease 7 17.5 15 38.5 0.05
Peripheral arterial disease 1 2.5 2 5.1 0.62
COPD 3 7.5 3 7.7 1.00
Prior stroke 5 12.5 4 10.3 1.00
Gastric tube feeding 27 67.5 25 64.1 0.82
Mechanical ventilation 6 15.0 1 2.5 0.11
Urinary catheters 37 92.5 39 100 0.24
Time delay to first dose [h] (mean, 95%CI) 24.0 20.3–27.7 24.0 20.8–27.2 0.70
Baseline parameters mean 95%CI of mean mean 95%CI of mean
Heart rate [beats/min] 81.7 76.2–87.2 77.6 72.4–82.9 0.24
Body temperature [uC] 37.0 36.9–37.2 37.0 36.8–37.2 0.69
Breathing rate, in patients breathing spontaneously
[breaths/min]
21.2 18.9–23.5 18.7 16.9–20.6 0.07
Systolic BP [mmHg] 161.6 154.3–168.8 159.0 150.8–167.2 0.55
Diastolic BP[mmHg] 76.8 71.0–82.6 74.5 70.0–79.0 0.54
Glucose [mg/dl] 146.4 130.9–162.0 144.3 129.2–159.3 0.88
C-reactive protein [mg/dl] 1.4 0.8–2.0 0.9 0.5–1.3 0.41
WBC610
9/L 9.3 8.3–10.4 9.0 8.0–10.1 0.70
MCA: middle cerebral artery; NIHSS: National Institute of Health Stroke Scale; COPD: chronic obstructive pulmonary disease; BP: blood pressure, WBC: white blood cells.
doi:10.1371/journal.pone.0002158.t001
The PANTHERIS Trial
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Microbiological analysis of microorganisms isolated from
patients in the placebo group with infections identified a typical
bacterial spectrum of early onset nosocomial pneumonia or
urinary tract infection (Table 3). The identification of relevant
pathogens was successful in 5 of 11 lower respiratory tract
infections and in 4 of 8 urinary tract infections. In the verum
group we identified one patient with post-stroke pneumonia
caused by methicillin-resistant Staphylococcus aureus (MRSA).
Analyzing microbiological isolates obtained from the same patient
before starting study medication revealed MRSA colonization.
Analysis of moxifloxacin resistance
We investigated ciprofloxacin and moxifloxacin susceptibility in
E. coli isolated from stool samples before and after treatment.
Before treatment, microbiological analysis of stool samples from 59
patients revealed that 40 patients, 20 in each treatment group,
were colonized with E. coli (Table 4). Susceptibility testing showed
that isolates from 39 patients were susceptible to ciprofloxacin and
moxifloxacin. One patient in the placebo group carried a mixed
culture of susceptible and resistant E. coli. Three days after the end
of the treatment period (day 9), stool samples of the same 20
patients of each study group revealed that E. coli could be re-
isolated from 3 patients of verum group (15%) and from 14
patients of placebo group (70%). Resistant isolates were detected
in the one patient from the placebo group, who was already
initially colonized by resistant E. coli (see above) and in one
additional patient in the verum group. Genetic analysis by MAMA
assay demonstrated that the gyrA (Ser-83) mutation was present in
resistant E. coli isolates but absent in all other susceptible isolates.
This indicates that fluoroquinolone resistance in both patients was
caused by known molecular changes in the DNA gyrase.
Mechanical ventilation
At study entry no patient was under mechanical ventilation
(MV). Within 11 days, seven patients (1 verum, 6 placebo) in the
ITT population (Table 1) and five patients (1 verum, 4 placebo) in
the PP population underwent MV. Frequencies of MV were not
significantly different between both treatment groups (Table 1).
Median time point for beginning of MV was at day 3 (range 1–8).
The MV of the verum-treated patient started at day 2. This
patient developed pneumonia on day five. From the 6 patients of
the placebo group which underwent MV (median day 3; range: 1–
8) two underwent intubation with clinical signs of pneumonia, and
in one patient MV was necessary four days after onset of
pneumonia (median day 3, range: 2–4). From the 7 patients
undergoing MV two (both from placebo group) died within one
month (day 22 and 30).
Daily maximum body temperature and C-reactive protein
Patient maximum body temperature per day did not differ
significantly between both treatment groups (ITT population; data
not shown). CRP levels from patients (ITT population) of the
placebo group increased significantly more than in the verum
group (p=0,0186; Figure 2). Comparing CRP levels univariately,
a significantly lower CRP concentration was found in the verum
group at days 3, 5, 6 and 7, which followed the treatment period
with an interval of one day (Figure 2).
Survival
To avoid a preselection bias, cumulative survival analyses are
based on ITT and not PP population, since patients who died
within the first 11 days after stroke without reaching the primary
endpoint were considered as ‘drop outs’ for PP population. Seven
(3 verum, 4 placebo) of 79 patients (8.9%) died within 11 days
after stroke onset. Within 6 month after stroke 13 (6 verum, 7
placebo) of 72 patients (18.1%) died, and 7 patients were lost in
follow-up (3 verum, 4 placebo). Survival did not differ significantly
between placebo and verum group 180 days after stroke onset
(Log Rank p=0.618, Figure 3). However, cumulative survival of
patients with infection compared to patients without infection was
significantly different (p,0.001) during follow-up period (Figure 4).
Patients with stroke-associated pneumonia had a significantly
Table 2. Incidence of infections in ITT and PP population
Treatment arm No infection n [%] infection n [%] Sum n
ITT population
Placebo 27 [67.5] 13 [32.5] 40
Verum 33 [84.6] 6 [15.4] 39
Sum 60 [75.9] 19 [24.1] 79
PP population
Placebo 18 [58.1] 13 [41.9] 31
Verum 29 [43.9] 6 [17.1] 35
Sum 47 [71.2] 19 [28.8] 66
The numbers and rates [in brackets] of infections in both treatment groups are
shown for ITT and PP populations, respectively.
doi:10.1371/journal.pone.0002158.t002
Table 3. Bacterial pathogens isolated from stroke patients
specified for pneumonia and urinary tract infection
Pneumonia (n=11) Placebo (n=8) Verum (n=3)
S. aureus (methicillin sensitive) 3
S. aureus (methicillin resistant) 1
S. pneumoniae 1
no pathogen 2 2
Not done 2
Urinary tract infection (n=8) Placebo (n=5) Verum (n=3)
E. coli 11
E. coli+Enterococcus faecalis 1
Proteus mirabilis 1
no pathogen 2 2
doi:10.1371/journal.pone.0002158.t003
Table 4. Susceptibility analysis of E. coli isolates
E. coli isolates before
treatment
E. coli isolates after
treatment
Treatment arm Sensitive
# n Resistant
## n Sensitive
# n Resistant
##
n
Placebo 20 1* 13 1*
Verum 20 0 2 1
#ciprofloxacin MIC #1 mg/L, moxifloxacin MIC #0.5 mg/L;
##ciprofloxacin MIC $4 mg/L, moxifloxacin MIC $2 mg/L;
*Isolated from a patient carrying a mixture of resistant and sensitive E. coli
isolates
doi:10.1371/journal.pone.0002158.t004
The PANTHERIS Trial
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without infections whereas patients with urinary tract infections
showed no differences in cumulative survival compared with
patients without infections (p=0.898, data not shown).
Neurological Outcome
Neurological outcome 6 month after stroke onset was deter-
mined by using the Barthel Index (BI) as a measure of limitations
in activities of daily living. Comparing both treatment arms after
dichotomization, in the ITT population the rate of patients with
good outcome (BI$60) was 64% in the verum group (14 out of 22)
compared to 55% in the placebo group (11 out of 20) (p=0.574).
In the PP population the rate of patients with good outcome was
67% in the verum group (14 out of 21) compared to 55% in the
placebo group (10 out of 18) (p=0.483). In ITT as well as PP
population, both treatment groups displayed the same median 70
(p=0.700; p=0.543). In the ITT population the rate of patients
with good outcome was 61% in the non-infection group (20 out of
Figure 2. Time course of CRP serum concentration. Time course of CRP levels in placebo and verum group shown by boxplots. Number of
patients is indicated by N. CRP levels in the moxifloxacin group are significant lower compared to the placebo group. The p-values for the main
effects are ,0.0001 for day of CRP measurement and 0.0186 for treatment (multivariate analysis of variance for repeated measurements on
logarithmically transformed data, no interaction model). The dependency between treatment and day of CRP measurement has a p-value of 0.0845
(interaction model). In patients of the verum group CRP concentration are significantly lower compared to patients of the placebo group 3, 5, 6, and
7 days after stroke (* p,0.05; ** p,0.005).
doi:10.1371/journal.pone.0002158.g002
Figure 3. Kaplan-Meier curves of survival in both treatment
groups. Crosses indicate time points when patients were lost to
follow-up (‘censored’; n=7; verum n=3, placebo n=4 placebo). Seven
(verum n=3, placebo n=4) of 79 patients (8.9%) died within 11 days
after stroke onset. Within 6 month after stroke 13 (verum n=6, placebo
n=7) of 72 patients (18.1%) died.
doi:10.1371/journal.pone.0002158.g003
Figure 4. Kaplan-Meier curves of survival in patients with and
without infections. Crosses indicate time points when patients were
lost to follow-up (‘censored’; n=7, infection n=1, no infection n=6).
Seven (no infection n=5, infection n=2) of 79 patients (8.9%) died
within 11 days after stroke onset. Within 6 month after stroke 13
(infection n=6, no infection n=7) of 72 patients (18.1%) died.
doi:10.1371/journal.pone.0002158.g004
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p=0.922). In the PP population the rate of patients with a BI$60
was 61% in the non-infection group (19 out of 31 patients)
compared to 63% in the infection group (5 out of 8, p=0.951).
Levels of monocytic HLA-DR expression
To determine the impact of cerebral ischemia on immune
competence in relation to the risk of post-stroke infections we used
a novel standardized assay to quantify the expression of monocytic
HLA-DR. All patients (PP population) showed signs of post-stroke
immunodepression, as indicated by significantly reduced mono-
cytic HLA-DR expression at days 1, 3, and 8 compared to 3 and
6 months after stroke (Figure 5a). There were no significant
differences in the time course of monocytic HLA-DR levels
between the placebo and verum group (Figure 5b). However,
infected patients in the placebo group had significantly lower
monocytic HLA-DR levels at days 1, 3, and 8, as shown in
Figure 6a. In contrast, no significant differences in monocytic
HLA-DR expression were observed between infected and non-
infected patients in the verum group at all time points (Figure 6b).
Notably, patients without infections in the verum group had
significantly lower monocytic HLA-DR levels at day 1 compared
to patients without infections in placebo group corroborating that
moxifloxacin treatment effectively prevented infections in a
proportion of these patients. At 6 month after stroke, monocytic
HLA-DR expression returned to normal levels and was not
signifcantly different between surviving patients with and without
infections in both groups (Figure 6a, b).
Risk factors of post-stroke infections
Infection rate within 11 days was significantly associated with
tube feeding, mechanical ventilation, treatment, and monocytic
HLA-DR levels at baseline (day 1 after stroke onset and before
study treatment onset) in univariate PP analysis of the placebo
group (Table 5). Comparing patients with and without infections
of both treatment arms in the PP population (data not shown) only
tube feeding was significantly more frequent in infected patients
(p=0.001). We performed regression analysis in PP population
adjusted for NIHSS at admission, age, tube feeding, mechanical
ventilation, monocytic HLA-DR expression at day 1 post stroke
and treatment arm, which revealed that treatment arm and the
interaction between treatment arm and HLA-DR expression were
the strongest independent predictors for post-stroke infections
(Table 6).
Adverse events
Table 7 shows types and frequencies of adverse events (AE) in
ITT population reported over the whole study period including
6 month follow-up. There were no serious adverse events other
than the above reported 19 cases of infections and 12 deaths of
patients. Overall 40 cardiovascular, neurological, gastrointestinal,
laboratory, and general medical AE were reported. Concerning
the frequency of AE both treatment groups did not differ. There
was no report of AE related to study medication.
Discussion
PANTHERIS, is an investigator-initiated, multi-center, rando-
mised, double-blind, placebo-controlled trial. PP analysis demon-
strates that preventive antibiotic therapy with moxifloxacin within
36 hours after stroke onset reduces infection rate in patients with
severe ischemic stroke in the territory of the middle cerebral
artery, while ITT analysis revealed only a trend towards beneficial
effects for this treatment strategy. Patients in the placebo group
were treated according to current treatment guidelines. With
respect to antibiotics, they were fully and effectively treated as soon
as antibiotic medication was indicated, i.e. as soon as an infection
was diagnosed [13,22]. Thus, PP analysis of our proof of principle
Figure 5. Time course in monocytic HLA-DR expression after stroke. a: Monocytic HLA-DR expression is significantly reduced in all patients
at days 1, 3, and 8 compared to 90 and 180 days after stroke (*** p,0.001). b: The time course of monocytic HLA-DR expression is not significantly
different between patients from the placebo and verum groups. Dashed lines indicate the upper and lower reference range for monocytic HLA-DR
levels in healthy individuals (5% percentile=18036 mAb/cell; 95% percentile=57958 mAb/cell).
doi:10.1371/journal.pone.0002158.g005
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preventive anti-infective therapy over current standard therapy.
Up to 95% of patients suffer from at least one relevant
complication within the first three months after stroke [1]. Thus,
for the majority of stroke patients, general measures targeting early
identification and treatment of complications remain the major
medical challenge. Complications impair functional and neuro-
logical outcome [2,4,8]. Treatment in dedicated stroke units was
demonstrated to reduce the incidence of stroke-associated
complications [23]. However, even in stroke units, infections after
stroke remain common complications with a frequency between
21 and 65% [3]. Among infections, pneumonia have the greatest
impact on the neurological outcome and mortality rate after stroke
[5,6,8,24]. Pneumonia represents the leading cause of in-hospital
mortality of stroke patients, accounting for 31% of all death [8].
Currently, post-stroke pneumonia is thought to be a conse-
quence of aspiration due to dysphagia and immobilization
[2,4,25–27]. Forty to 70% of patients develop dysphagia within
3 days after stroke, 40% of them aspirate and approximately one
third develop pneumonia [10,28]. As stroke patients with
dysphagia are at risk for pneumonia, post-stroke pneumonia is
thought to be a preventable complication. Once dysphagia is
diagnosed, measures can be taken aimed at prevention of
aspiration [28,29]. Feeding tubes are often used to prevent
aspiration pneumonia [25,30] but were also identified as the
strongest independent predisposing factor for acute post-stroke
infections [31]. In the PANTHERIS population, tube feeding is
associated with a significantly higher risk of infections, however, it
was not an independent risk factor for infections. Results from the
large FOOD trials suggest that early tube feeding neither prevents
nor favours infection rates [32].
Although post-stroke aspiration increases the risk of developing
pneumonia by sevenfold, aspiration alone is not sufficient to
explain the high incidence of pneumonia in acute stroke
[2,4,25,26,33]. About 50% percent of healthy subjects also
aspirate pharyngeal secrets every night to a similar extend as
stroke patients, however, without developing pneumonia [34,35].
Thus, our understanding of the high incidence of pneumonia in
stroke patients is still incompletely. Since several immune
dysfunctions have been reported in patients with acute CNS
injury, stroke-induced changes in immunity may explain the high
incidence of infections [3,36,37]. In a murine model of cerebral
ischemia we provided experimental proof that a neuro-endocrine-
mediated systemic immunodepression is an essential cause for a
decreased antibacterial defense after acute ischemic stroke leading
to post-stroke pneumonia [38]. We further demonstrated that
otherwise harmless minor bacterial aspiration leads to severe
pneumonia and bacteriemia after ischemic stroke suggesting that
the deleterious combination of stroke-induced immunodeficiency
with stroke-facilitated aspiration dramatically increases the
susceptibility to infection [39]. Results from the PANTHERIS
trial provides further evidence for a stroke-induced immunode-
pression in stroke patients causing post-stroke infections. As
marker for immune competency we measured the monocytic
HLA-DR expression, which is a well known and sensitive marker
for a disturbed immune function in septic and critically ill patients
[17,40–42]. Here we describe a significantly reduced monocytic
HLA-DR expression in the very early phase after stroke compared
to 3 and 6 months after stroke. Remarkably, patients with
infections in the placebo, but not verum group had significantly
lower monocytic HLA-DR levels at days 1, 3, and 8 compared to
non-infected patients. Notably, patients without infections in the
verum group had significantly lower monocytic HLA-DR levels at
the first day after stroke onset compared to patients without
infections in placebo group corroborating that moxifloxacin
treatment effectively prevented infections in a proportion of these
Figure 6. Monocytic HLA-DR expression in patients with and without infections. a: In the placebo group, monocytic HLA-DR expression in
patients with infections is significantly reduced compared to patients without infections at day 1 (** p=0.003), 3 (** p=0.005), and 8 (*** p,0.001)
days, but not at day 180 after stroke. b: In the verum group, monocytic HLA-DR expression is not significantly different between patients with and
without infections. Dashed lines indicate the upper and lower reference range for monocytic HLA-DR levels in healthy individuals (5%
percentile=18036 mAb/cell; 95% percentile=57958 mAb/cell).
doi:10.1371/journal.pone.0002158.g006
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day 1 after stroke and before study treatment onset was a strong
independent predictor of subsequent post-stroke infections in the
placebo group, but not in the moxifloxacin group. Since there
were no significant differences in the time course of monocytic
HLA-DR levels between the placebo and verum groups, it is
rather unlikely that post-stroke infections by itself cause the
reduced HLA-DR expression.
Since the established general measures do not effectively
prevent post-stroke infections, and in the light of our pathophys-
iological concept [36] of post-stroke infections and our preclinical
data [38], Preventive Antibacterial Therapy (PAT) warrants
further attention as promising new strategy. Using our experi-
mental model of post-stroke infections, we have demonstrated that
post-stroke infections can effectively be reduced by preventive
antibiotic therapy with moxifloxacin. More importantly, in this
stroke model moxifloxacin not only prevents the development of
infections and fever, it also significantly reduces mortality, and
improves neurological outcome [11]. Consequently, the primary
endpoint of the PANTHERIS trial aimed at preventing severe
stroke-associated infections, in particular pneumonia. Based on a
retrospective analysis of stroke patients in participating stroke units
infections arise between 2 and 7 days after stroke onset (data not
shown). In order to cover this critical time period effectively, in
Table 5. Univariate analysis for predictors of post-stroke infections in the placebo arm of PP population.
Infection (N=13) No Infection (N=18) P
n% n %
male:female 6/7 46.2/53.8 6/12 33.3/66.7 0.710
Right:left MCA 4/9 30.8/69.2 8/10 44.4/55.6 0.484
Age (95%CI) 75.1 68.5–81.6 70.3 64.9–75.7 0.154
NIHSS ad admission (Median,min-max) 17 13–25 14.5 12–20 0.080
NIHSS 180 days. (Median,min-max) 11.5 4–16 5 1–14 0.108
Qualifying event
Cardioembolism 8 61.5 7 38.9 0.285
Atherothrombotic 5 38.5 6 33.3 1.000
Small-vessel 0 0.0 1 5.6 1.000
Other 0 0.0 2 11.1 0.497
Unknown 0 0.0 2 11.1 0.497
Risik factors
Hypertension 7 53.8 13 72.2 0.449
Diabetes mellitus 4 30.8 7 38.9 0.718
Current smoking 3 23.1 2 11.1 0.625
Hypercholesterinemia 3 23.1 2 11.1 0.625
Atrial fibrillation 5 38.5 7 38.9 1.000
Malignoma 1 7.7 2 11.1 1.000
Coronary heart disease 2 15.4 2 11.1 1.000
Peripheral arterial disease 0 0.0 0 0.0 NA
COPD 2 15.4 0 0.0 0.168
Prior Stroke 1 7.7 3 16.7 0.621
Tube feeding 11 84.60 8 44.40 0.032
Urinary catheters 13 100.00 15 83.30 0.245
Mechanical ventilation 4 30.80 0 0.00 0.023
Delay to first dose h (mean, 95%CI) 28.6 19.9–37.3 20.9 16.3–25.5 0.173
Baseline parameters mean 95%CI of mean mean 95%CI of mean
Heart beats [/min] 68.5 75.0–97.9 78.2 70.8–85.6 0.346
Temperature [uC] 37.1 36.9–37.4 36.9 36.6–37.1 0.097
Breathing frequency [/min] 19.3 13.8–24.9 22.4 18.4–26.4 0.472
Systolic BP [mmHg] 166.3 151.1–181.5 159.5 147.4–171.6 0.446
Diastolic BP[mmHg] 82.1 74.4–89.7 76.9 67.8–86.0 0.326
Glucose [mg/dl] 143.6 124.6–162.7 160.3 128.1–192.4 0.781
C-reactive protein [mg/dl] 0.988 0.317–1.659 1.070 0.420–1.720 0.737
WBC610
9/L 9.0 7.6–10.4 8.6 7.4–9.8 0.594
mHLA-DR [antib./cell] 17273 12197–22349 28541 23521–33561 0.003
Tube feeding, mechanical ventilation, and expression of mHLA-DR were associated univariately with post-stroke infection.
doi:10.1371/journal.pone.0002158.t005
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onset and continued for 5 days. In order to ensure that preventive
antibacterial therapy not only shifts infections to a later time point
infection rate was studied within 11 days post stroke. In the per
protocol analysis, PANTHERIS demonstrated the efficacy of
preventive anti-infective therapy with moxifloxacin. Compared to
an infection rate of 41.9% in the standard therapy (placebo) group,
only 17.1% of verum treated patients suffered from infections.
Further evidence for the efficacy of preventive anti-infective
therapy is the significant reduction of C-reactive protein in the
moxifloxacin treated group, compared with placebo. Of all
infections, predominantly pneumonia seems to be prevented,
although this difference did not reach statistic significance.
Mechanical ventilation, a known strong risk factor for nosocomial
pneumonia [43], appeared to be more frequent in placebo
compared to moxifloxacin group, again without reaching statistical
significance level. Although we cannot exclude an inclusion bias, it
would seem rather unlikely that the higher pneumonia rate in the
placebo group should be caused by the higher frequency of
mechanical ventilation in this group. On the contrary, since
pneumonia preceded mechanical ventilation in the placebo-
treated patient, our data suggest that PAT might reduce the need
for mechanical ventilation in patients with acute stroke.
Stroke-associated infections lead to poor outcome [3], however
the support for an independent causal relationship between
infections and poor neurological outcome was recently challenged
[37]. The PANTHERIS trial confirms that infections are
associated with a significantly reduced survival rate. However,
we remained short of demonstrating that patients treated with
moxifloxacin should have improved clinical outcome or increased
survival rate at 6 months after stroke, compared with patients
treated according to current standards. These results seem to
support the conclusion that stroke-associated infections are not
the cause but rather a marker for a poor neurological outcome
following stroke. However, since PANTHERIS was not
sufficiently powered to address this issue, it remains open
whether post-stroke infections lead to a worse outcome in stroke
or not.
Chamorro and co-workers were the first to investigate in a
randomized, placebo-controlled, double-blind trial the effect of
preventive antibiotic therapy in stroke [44]. Their single-center
ESPIAS trial included 136 patients using levofloxacin in a dose of
500 mg/d for 3 days starting within 24 hours after stroke onset.
Table 6. Logistic regression analysis of independent predictors for post-stroke infections
Effect Parameter estimation Standard p-value
Estimate 95% Confidence Interval error
Lower Upper
Model
Treatment 0.015
Interaction: treatment and HLA-DR 0.036
Estimates
Intercept 212.7 238.4 13.1 13.1 0.336
Treatment 47.2 9.0879 85.4014 19.5 0.015
HLA-DR level in verum arm 1.113 21.4563 3.6827 1.311 0.396
HLA-DR level in placebo arm 23.507 26.3319 20.6822 1.441 0.015
Shown are the nominal p-values and estimates for the parameters remaining in the model after backward selection. Factors and covariates included for selection were:
NIHSS at admission, age, tube feeding, mechanical ventilation, HLA-DR expression (Day 1), treatment, and interaction between treatment and HLA-DR (Day 1)
expression. The final logistic model was: log( p/1-p)=m+treatment+ßtreatment
*log(HLA-DR); p: number of infected patients within 11 days/total number of patients (in
the respective treatment group).
doi:10.1371/journal.pone.0002158.t006
Table 7. Safety analysis
Placebo
(n=40)
Verum
(n=39)
n% n % p
1 AE 14 35 9 22.5 0.32
$2 AE 2 5 5 12.5 0.43
Pulmonary 3 7.5 0 0 0.24
Dyspnoea 2 5 0 0
Pneumothorax 1 2.5 0 0
Neurological 4 10 8 20.5 0.23
Increased intracranial pressure 2 5 2 5.1
Hemorrhagic transformation of stroke 1 2.5 2 5.1
Seizures 1 2.5 1 2.6
Recurrent stroke 0 0 1 2.6
Frontal lobe syndrome 0 0 1 2.6
Hallucination 0 0 1 2.6
Cardiac arrhythmia 1 2.5 1 2.6 1
Ventricular tachycardia 1 2.5 0 0
Sinus bradycardia 0 0 1 2.6
Gastrointestinal 4 10 3 7.7 1
Abdominal pain 1 2.5 0 0
Diarrhea 2 5 2 5.1
Nausea/Vomitting 1 2.5 1 2.6
Laboratory changes 2 5 4 10.3 0.43
Hypothyreosis 1 2.5 0 0
Hyponatriaemia 1 2.5 0 0
Alanine aminotransferase increased 0 0 1 2.6
Blood creatine phosphokinase increased 0 0 1 2.6
Haemoglobin decreased 0 0 1 2.6
Hypocalcaemia 0 0 1 2.6
Other 1 2.5 3 7.7 0.36
Arthralgia 0 0 2 5.1
Hemolysis 0 0 1 2.6
Pharyngeal bleeding 1 2.5 0 0
doi:10.1371/journal.pone.0002158.t007
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stopped since levofloxacin neither prevented post-stroke infections
nor improved outcome in patients with ischemic or hemorrhagic
stroke. ESPIAS even suggested a non-significant rise of mortality
rate in the verum group. Although both trials are similar in design,
several differences may explain the discordant results. For
example, in ESPIAS patients were treated sooner but shorter
after stroke onset compared to PANTHERIS. Since the majority
of stroke-associated infections occur within five days after stroke
onset [33,45,46], the longer treatment period in PANTHERIS
may be a crucial advantage covering this critical time period.
Furthermore, in PANTHERIS moxifloxacin was chosen for its
superior effect against aerobic pathogens [47], as local epidemi-
ological data of stroke patients (unpublished data) demonstrated a
predominating Gram positive spectrum (Streptococcus pneumoniae,
Staphylococcus aureus) in pneumonia with a low incidence of
moxifloxacin resistant pathogens such as MRSA and Pseudomonas
aeruginosa. In addition, in vitro antibacterial activity of moxifloxacin
against anaerobes is superior compared to levofloxacin [48], which
might be of relevance, since anaerobic pathogens need consider-
ation in aspiration pneumonia [49].
A major drawback of preventive antibiotic therapy is the
potential induction of antibiotic resistance. The observation that
susceptible E. coli isolates from one patient became resistant during
moxifloxacin treatment indicates selection of fluoroquinolone-
resistant bacteria by preventive treatment with moxifloxacin.
However, the low E. coli re-isolation rate of 15% among patients
treated with moxifloxacin (as compared to 70% in the placebo
group) suggests moxifloxacin affects normal gut flora and was
effective enough to eradicate E. coli in 17 out of 20 patients. The
fact that in six patients of the placebo group, E. coli could not be
re-isolated after treatment suggests that the intestinal E. coli
populations were not solely affected by moxifloxacin treatment.
In conclusion, PP analysis of PANTHERIS suggests that
preventive antibiotic therapy with moxifloxacin reduces the
infection rate in patients with severe ischemic stroke in the
MCA territory. Since PANTHERIS as proof of concept trial was
not designed to demonstrate clinical superiority of preventive
antibacterial treatment in a routine environment and ITT analysis
revealed only a trend towards beneficial effects of preventive
antiinfective treatment caution is needed. Analyses of secondary
endpoints demonstrate a significant lower survival rate during
6 month follow-up for patients with infections. Even though
infection rate was reduced in patients treated with moxifloxacin,
survival and neurological outcome were not significantly improved
compared to placebo. PANTHERIS provides the framework of
data for our current planning of a phase III trial to further
investigate the innovative concept of preventive antibacterial
therapy in stroke patients focussing on effectiveness rather than
efficacy. If post-stroke infections are independent risk factors for
poor outcome and if they can be effectively prevented, there will
be an urgent need for predicting factors of post-stroke infections.
Indicators of immunodepression such as monocytic HLA-DR
expression may be interesting candidate markers to identify
patients at high risk for infectious complications, which warrant
further confirmation in prospective trials.
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